Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)

Schneider, Lon S.; Olin, Jason T.; Doody, Rachelle S.; Clark, Christopher M.; Morris, John C.; Reisberg, Barry; Schmitt, Frederick A.; Grundman, Michael; Thomas, Ronald G.; Ferris, Steven H.

doi:10.1007/978-1-4612-4116-4_64

Cited by 269 publications

(297 citation statements)

References 8 publications

Supporting

Mentioning

291

Contrasting

Unclassified

Order By: Relevance

“…Secondary outcome measures included the ADCS Clinical Global Impression of Change (ADCS-CGIC), 23 the MMSE, the Dependence Scale, 24 the ADCS Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory (NPI), 25 and 3 supplemental cognitive tests from the ADCS instrument protocol, including Maze A2, a measure of executive function; Number Cancellation, a measure of visual attention; and Delayed Word Recall. 26 Quality of life (QOL) was measured with is a 13-item scale which ranges from 0 to 52, with a higher score indicative of a better QOL.…”

Section: Methods Study Designmentioning

confidence: 99%

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

Sano¹,

Bell²,

Galasko³

et al. 2011

Neurology

269

187

View full text Add to dashboard Cite

show abstract

Section: Methods Study Designmentioning

confidence: 99%

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

Sano¹,

Bell²,

Galasko³

et al. 2011

Neurology

269

187

View full text Add to dashboard Cite

show abstract

“…It is the same as the CGIC used for the dose finding study in the U.S. In the U.S., the Clinician's InterviewBased Impression of Change (CIBIC) (58) and AD Cooperative Study -Clinical Global Impression of Change (ADCS -CGIG) (59) have been developed with the objective of supplementing the low reliability of the CGIC. However, these systems do no suit actual conditions in Japan because clinicians other than the attending physicians must make evaluations based on interviews with the patients before and after treatment.…”

Section: ) Outline Of the Study Methodsmentioning

confidence: 99%

Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor

Sugimoto

Ogura

Arai

et al. 2002

Japanese Journal of Pharmacology

197

127

View full text Add to dashboard Cite

ABSTRACT-A wide range of evidence shows that cholinesterase (ChE) inhibitors can interfere with the progression of Alzheimer's disease (AD). The earliest known ChE inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of AD patients. However, clinical studies show that physostigmine has poor oral activity, brain penetration and pharmacokinetic parameters, while tacrine has hepatotoxic liability. Studies were then focused on finding a new type of acetylcholinesterase (AChE) inhibitor that would overcome the disadvantages of these two compounds. During the study, by chance we found a seed compound. We then conducted a structure-activity relationship study of this compound. After four years of exploratory research, we found donepezil hydrochloride (donepezil). Donepezil showed several positive characteristics including the following: 1) It has a novel structure compared to other conventional ChE inhibitors; 2) It shows strong anti-AChE activity and has long lasting efficacy; 3) The inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility; 4) The results of clinical studies on donepezil show a very high significant difference on ADAS cog and CIBIC plus scores of AD patients. Donepezil is currently marketed in 56 countries all over the world.

show abstract

“…The CGIC is a global assessment of clinical change over time, based on the clinician's overall impression of change in cognitive, behavioral, and functional symptoms (26). Change over time is rated on a 7-point scale from "very much improved" to "very much worse.…”

Section: Ad Cooperative Study -Clinician's Global Impression Of Changmentioning

confidence: 99%

Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial

Sultzer

Davis²,

Tariot³

et al. 2008

AJP

Self Cite

271

167

View full text Add to dashboard Cite

Objective-To measure the effects of atypical antipsychotic medication on psychiatric and behavioral symptoms in patients with Alzheimer's disease (AD) and psychosis or agitated behavior.Method-The CATIE-AD effectiveness study included 421 outpatients with AD and psychosis or agitated/aggressive behavior. Patients were assigned randomly to masked flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks. Patients could be rerandomized to a different medication treatment at the clinician's discretion, which ended the Phase 1 period. Psychiatric and behavioral symptoms, functional abilities, cognition, care needs, and quality of life were measured at regular intervals.

show abstract

Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)

Cited by 269 publications

References 8 publications

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor

Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial

Contact Info

Product

Resources

About